ABSTRACT
Background Effects of timing of Convalescent plasma (CP) administration on hospitalized COVID-19 patients are not established.
Methods We used the National COVID Cohort Collaborative data to perform a retrospective cohort study of hospitalized COVID-19 patients in the United States between 07-01-2020 and 12-19-2020. We stratified patients based on day of CP administration (Day 0, 1, 2, 3 and 4) from COVID-19 diagnosis. We used 35 predictors to frame matched cohorts accounting for clinical and sociodemographic characteristics. We used competing risk survival models to examine the association between CP administration and length of hospital stay with in-hospital death as a competing risk performing Gray’s test on the cumulative incidence function and Cox’s regression on cause specific hazard ratios.
Results In a cohort of 4,003 hospitalized COVID-19 patients, 197 (4.9%) received CP within the first 5 days following COVID-19 diagnosis. After adjusting for potential confounding variables, there were no statistically significant associations between day of CP administration and length of hospital stay. Day 0 CP administration signallled lower mortality but was not statistically significant (HR 0.45 [0.19-1.03]).
Conclusions We found no association between the timing of CP administration and length of stay among hospitalized COVID-19 patients.
Competing Interest Statement
Joy Alamgir is founder of ARIScience. Dr. Alexander is past Chair and a current member of FDA's Peripheral and Central Nervous System Advisory Committee; is a co-founding Principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation; and is a past member of OptumRx's National P&T Committee. Brian Garibaldi has received consulting fees from Janssen Research and Development, LLC and serves on the FDA Pulmonary-Asthma Drug Advisory Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies
Funding Statement
This research was partially funded by ARIScience. The N3C data project which this research utilized was funded by National Institutes of Health NCATS U24 TR002306.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National Institute of Health's (NIH) National COVID Cohort Collaborative (N3C) Data Utilization Request Approval committee approved the data utilization request of this project (RP-C80011)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
National Institute of Health's (NIH) National COVID Cohort Collaborative (N3C) has clear procedures for researchers to gain access to the data (1000+ researchers already have access to the data) and as such the patient statistical analysis of this manuscript is transparent and repeatable. https://ncats.nih.gov/n3c provides data access request process details. Supplementary materials to this manuscript provided at https://www.ariscience.org/p3_sc2_paper_03.html include R analysis code.
